secwatch / observer
8-K filed October 5, 2023, 7:59 PM ET ticker IMDX CIK 0001642380
other material confidence high sentiment neutral materiality 0.40

Insight Molecular Diagnostics Inc. (IMDX): auditor change — Oncocyte dismisses Withum, engages Marcum as independent auditor for FY 2023

Insight Molecular Diagnostics Inc.

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Insight Molecular Diagnostics Inc. engaged Marcum LLP as its auditor.

Action
engagement
Auditor
Marcum LLP
Exact text from the filing
the Audit Committee approved the engagement of Marcum LLP (“ Marcum ”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, subject to Marcum’s completion of their client acceptance procedures.
View on SEC.gov
Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Insight Molecular Diagnostics Inc. dismissed WithumSmith+Brown, PC as its auditor.

Action
dismissal
Auditor
WithumSmith+Brown, PC
Successor
Marcum LLP
Exact text from the filing
The Company has dismissed WithumSmith+Brown, PC (“ Withum ”) as independent registered public accounting firm of the Company on September 29, 2023.
View on SEC.gov

Browse all auditor changes →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-036351
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.